Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera

Haematologica

Volumn 97, Issue 4, 2012, Pages 538-542

  Kuriakose, Emil ^a   Vandris, Katherine ^a   Lynn Wang, Y ^a   Chow, William ^a   Jones, Amy V ^b,c   Christos, Paul ^a   Cross, Nicholas C P ^b,c   Silver, Richard T ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b SALISBURY DISTRICT HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

Author keywords

JAK2V617F; Molecular response; Polycythemia vera; Reduced allele burden

Indexed keywords

BUSULFAN; DASATINIB; HYDROXYUREA; IMATINIB; JANUS KINASE 2; PEGINTERFERON ALPHA2A; PHOSPHORUS 32; RECOMBINANT ALPHA2B INTERFERON;

ADULT; ARTICLE; DRUG DOSE INCREASE; FEMALE; FOLLOW UP; GENE; GENE MUTATION; HEMATOLOGICAL PARAMETERS; HUMAN; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; PHLEBOTOMY; POLYCYTHEMIA VERA; PYROSEQUENCING; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; JANUS KINASE 2; MIDDLE AGED; MUTATION; POLYCYTHEMIA VERA; REMISSION INDUCTION; TREATMENT OUTCOME;

EID: 84859448466     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.053348     Document Type: Article

References (30)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Greisshammer M, et al. Phila - delphia-Negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol. 2011;29(6):761-770.
3. Wang YL, Vandris K, Jones A, Cross NC, Christos P, Adriano F, et al. JAK2 Mutations are present in all cases of polycythemia vera. Leukemia. 2008;22(6):1289.
4. Chen Q, Lu P, Jones AV, Cross NC, Silver RT, Wang YL. Amplification refractory mutation system, a highly sensitive and simple polymerase chain reaction assay for the detection of JAK2 V617F mutation in chronic myeloproliferative disorders. J Mol Diagn. 2007;9(2):272-276.
5. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22(1):14-22.
6. Barosi G, Birgegard G, Finazzi G, Geisshammer M, Harrison C, Hasselbalch HC, et al. Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference. Blood. 2009;113(20):4829-4833.
7. Kiladjian JJ, Cassinat B, Chevret S, Turlure P, Cambier N, Roussel M, et al. Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera. Blood. 2008;112 (8):3065-3072.
8. Quintas-Cardama A, Kantarjian H, Manshouri T, Luthra R, Estrov Z, Pierce S, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol. 2009;27(32):5418-5424.
9. Silver RT, Vandris K, Wang YL, Adriano F, Jones AV, Christos PJ, et al. JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. Leuk Res. 2011;35(2):177-182.
10. Besses C, Alvarez-Larran A, Martinez-Aviles L, Mojal S, Longaron R, Salar A, et al. Modulation of JAK2 V617F allele burden dynamics by hydroxycarbamide in polycythaemia vera and essential thrombocythaemia patients. Br J Haematol. 2011; 152(4):413-419.
11. Girodon F, Schaeffer C, Cleyrat C, Mounier M, Lafont I, Santos FD, et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica. 2008;93 (11):1723-1727.
12. Ricksten A, Palmqvist L, Johansson P, Andreasson B. Rapid decline of JAK2V617F levels during hydroxyurea treatment in patients with polycythemia vera and essential thrombocythemia. Haematologica. 2008;93(8):1260-1261.
13. Sirhan S, Lasho TL, Hanson CA, Mesa RA, Pardanani A, Tefferi A. The presence of JAK2V617F in primary myelofibrosis or its allele burden in polycythemia vera predicts chemosensitivity to hydroxyurea. Am J Hematol. 2008;83(5):363-365.
14. Spanoudakis E, Bazdiara I, Kotsianidis I, Margaritis D, Goutzouvelidis A, Christo-Foridou A, et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and polycythemia vera (PV) patients. Ann Hematol. 2009; 88(7):629-632.
15. Antonioli E, Carobbio A, Pieri L, Pancrazzi A, Guglielmelli P, Delaini F, et al. Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. Haematologica. 2010;95(8):1435-1458.
16. Larsen TS, Pallisgaard N, de Stricker K, Moller MB, Hasselbalch HC. Limited efficacy of hydroxyurea in lowering of the JAK2 V617F allele burden. Hematology. 2009;14(1):11-15.
17. Theocharides A, Passweg JR, Medinger M, Looser R, Li S, Hao-Shen H, et al. The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders. Haematologica. 2008;93(12):1890-1893.
18. Silver RT. Imatinib mesylate (Gleevec(TM)) reduces phlebotomy requirements in polycythemia vera. Leukemia. 2003;17(6):1186-1187.
19. Jones CM, Dickinson TM. Polycythemia vera responds to imatinib mesylate. Am J Med Sci. 2003;325(3):149-152.
20. Jones AV, Silver RT, Waghorn K, Curtis C, Kreil S, Zoi K, et al. Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. Blood. 2006;107(8):3339-3341.
21. Berlin NI, Wasserman LR. Polycythemia vera: A retrospective and reprise. J Lab Clin Med. 1997;130(4):365-373.
22. Donovan PB, Kaplan ME, Goldberg JD, Tatarsky I, Najean Y, Silberstein EB, et al. Treatment of Polycythemia Vera with Hydroxyurea. Am J Hematol. 1984;17(4): 329-334.
23. Vannucchi AM, Antonioli E, Guglielmelli P, Pardanani A, Tefferi A. Clinical correlates of JAK2V617F presence or allele burden in myeloproliferative neoplasms: a critical reappraisal. Leukemia. 2008;22(7):1299-1307.
24. Messora C, Bensi L, Vecchi A, Longo R, Giacobbi F, Temperani P, et al. Cytogenetic conversion in a case of polycythaemia vera treated with interferon-alpha. Br J Haematol. 1994;86(2):402-404.
25. Kiladjian JJ, Cassinat B, Turlure P, Cambier N, Roussel M, Bellucci S, et al. High molecular response rate of polycythemia vera patients treated with pegylated interferon alpha-2a. Blood. 2006;108(6):2037-2040.
26. Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH, IKZF1. Leukemia. 2010;24(6):1128-1138.
27. Silver RT, Bourla MH, Vandris K, Fruchtman S, Spivak JL, Feldman EJ, et al. Treatment of polycythemia vera with imatinib mesylate. Leuk Res. 2012;36(2):156-162.
28. Leukemia and Hematosarcoma Cooperative Group, European Organization for Research on Treatment of Cancer (E.O.R.T.C.). Treatment of polycythaemia vera by radiophosphorus or busulphan: a randomized trial. Br J Cancer. 1981;44(1):75-80.
29. Brodsky I. Busulfan versus hydroxyurea in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET). Am J Clin Oncol. 1998;21(1):105-106.
30. Gangat N, Strand J, Lasho TL, Finke CM, Knudson RA, Pardanani A, et al. Cyto - genetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates. Eur J Haematol. 2008;80 (3):197-200.